TROP2 Targeted Therapy: Module

CME

TROP-2–Targeted Therapy: Redefining the Therapeutic Landscape in HER2-Negative Breast Cancer

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: February 22, 2024

Expiration: February 21, 2025

Komal Jhaveri
Komal Jhaveri, MD, FACP

Activity

Progress
1 2
Course Completed

References

  1. Sakach E, Sacks R, Kalinsky K, et al. Trop-2 as a therapeutic target in breast cancer. Cancers (Basel). 2022;14:5936.
  2. Sacituzumab govitecan [prescribing information]. Foster City, CA: Gilead Sciences, Inc; 2023.
  3. Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6:22496-512.
  4. Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019;11:987-995.
  5. Kopp A, Hofsess S, Cardillo TM, et al. Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release. Mol Cancer Ther. 2023;22:102-111.
  6. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529-1541.
  7. Bardia A, Tolaney SM, Loirat D, et al. Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): final results from the phase 3 ASCENT study. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 1071.
  8. Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1423-1433.
  9. Tolaney SM, Bardia A, Marmé F, et al. Final overall survival analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan in patients with hormone receptor-positive/HER2-negative metastatic breast cancer. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 1003.
  10. Shimizu T, Sands J, Yoh K, et al. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 2023;10;41:4678-4687.
  11. Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329-2340.
  12. Yasuda S, Maejima T, Toki T, et al. Evaluation of bystander antitumor effect of Dato-DXd in TROP2 (+) and TROP2 (-) lung cell lines admixed tumor xenograft mouse models. Presented at: 2023 American Association for Cancer Research Annual Meeting; April 14-19, 2023. Abstract 4893.
  13. Bardia A, Krop I, Meric-Bernstam F, et al. Datopotamab deruxtecan (Dato-DXd) in advanced triple-negative breast cancer (TNBC): updated results from the phase 1 TROPION-PanTumor01 study. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract P6-10-03.
  14. Meric-Bernstam F, Krop I, Juric D, et al. Phase 1 TROPION-PanTumor01 study evaluating datopotamab deruxtecan (Dato-DXd) in unresectable or metastatic hormone receptor-positive/HER2-negative breast cancer (BC). Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract PD13-08.
  15. Bardia A, Jhaveri K, Im S, et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): primary results from the randomised phase III TROPION-Breast01 trial. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract LBA11.
  16. Ouyang Q, Yin Y, Song L, et al. SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): results from a phase I/II, single-arm, basket trial. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract 380MO.
  17. Coates JT, Sun S, Leshchiner I, et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discov. 2021;11:2436-2445.
  18. Trastuzumab deruxtecan [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo Inc; 2022.
  19. Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097-5108.
  20. Ogitani Y, Hagihara K, Oitate M, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039-1046.
  21. Abelman R, Spring L, Fell G, et al. Sequencing antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (A3 study): multi-institution experience and biomarker analysis. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract PS08-03.
  22. Poumeaud F, Morisseau M, Luc Cabel L, et al. Efficacy of sacituzumab-govitecan (SG) post trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract PS08-02.
  23. Huppert L, Reshma Mahtani R, Fisch S, et al. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. PS08-04.
  24. Fenton MA, Tarantino P, Graff SL. Sequencing antibody drug conjugates in breast cancer: exploring future roles. Curr Oncol. 2023;30:10211-10223.
  25. Schmid P, Wysocki PJ, Ma CX, et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase Ib/II study. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract 379MO.